Finance

Beta
Lists
MOLN:NASDAQ
Molecular Partners AG
$3.88
-1.77%
(-0.070) 1D
Jun 9, 9:52:34 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MOLN...
Open
$3.82
High
$3.88
Low
$3.67
Mkt. cap
156.41M
Avg. vol.
5.41K
Volume
2.15K
52-wk high
$5.36
52-wk low
$3.41
EPS
-$1.96
Beta
1.00
Shares outstanding
40.38M
No. of employees
134
Open
$3.82
High
$3.88
Low
$3.67
Mkt. cap
156.41M
Avg. vol.
5.41K
Volume
2.15K
52-wk high
$5.36
52-wk low
$3.41
EPS
-$1.96
Beta
1.00
Shares outstanding
40.38M
No. of employees
134
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to MOLN in the past 3 months
Strong Buy
Buy
4
Hold
0
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MOLN in the last 3 months.
Highest
Current $3.88
$13.00 (+235.05%)
Average
$11.00 (+183.51%)
Lowest
$8.00 (+106.19%)
News stories
From sources across the web
Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
About Molecular Partners AG
CEO-
Employees134
Founded2004
Headquarters-
SectorBiotechnology
Websitemolecularpartners.com
Last report
Jun 3, 2026
Fiscal period
Q1 2026
EPS / Est. (CHF)
-CHF 0.35 / -CHF 0.33
-6.06%miss
Revenue / Est. (CHF)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
10.71M
8.33M
8.18M
9.44M
Cost of revenue
10.71M
8.33M
8.18M
9.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.99M
3.60M
4.48M
4.00M
Operating expense
3.99M
3.60M
4.48M
4.00M
Total operating expenses
14.70M
11.93M
12.67M
13.44M
Operating income
-14.70M
-11.93M
-12.67M
-13.44M
Other non operating income
-3.00K
-2.00K
-5.00K
-4.00K
EBT including unusual items
-20.40M
-11.84M
-12.64M
-13.14M
EBT excluding unusual items
-17.78M
-11.72M
-12.69M
-13.14M
Income tax expense
-
-
4.00K
-
Effective tax rate
-
-
-0.03%
-
Other operating expenses
-
-
-
-
Net income
-20.40M
-11.84M
-12.65M
-13.14M
Net profit margin
-
-
-
-
Earnings per share
-0.56
-0.33
-0.36
-0.35
Interest and investment income
420.00K
366.00K
234.00K
176.00K
Interest expense
-4.00K
-3.00K
-6.00K
-7.00K
Net interest expenses
416.00K
363.00K
228.00K
169.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.15M
-11.40M
-12.44M
-12.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer